13 Lung Cancer 1 1 0 29 29 134 http://clinicaltrials.dfhcc.harvard.edu/trials/134 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer RATIONALE: Wedge resection or segmentectomy may be less invasive types of surgery than lobectomy for non-small cell lung cancer and may have fewer side effects and improve recovery. It is not yet known whether wedge resection or segmentectomy are more effective than lobectomy in treating stage IA non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying different types of surgery to compare how well they work in treating patients with stage IA non-small cell lung cancer. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 3 347 http://clinicaltrials.dfhcc.harvard.edu/trials/347 Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab also may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab after surgery may kill any tumor cells that remain after surgery. It is not yet known whether chemotherapy is more effective with or without bevacizumab in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying chemotherapy and bevacizumab to see how well they work compared to chemotherapy alone in treating patients with stage IB, stage II, or stage IIIA non-small cell lung cancer that was removed by surgery. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 3 1249 http://clinicaltrials.dfhcc.harvard.edu/trials/1249 Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles Research studies have shown a strong association between cancer and blood clots in the veins (also known as deep vein thrombosis). These blood clots can flow to the lungs (pulmonary embolism) which in severe cases may be life threatening. The purpose of this research study is to see if enoxaparin is effective in preventing blood clots in the veins in participants who have cancer of the lung, colon, or pancreas and also have high levels of tissue factor bearing microparticles in their blood (TFMP). TFMP are small particles that are generated from different types of blood cells in the body. In people who have cancer, TFMP are thought to be generated from cancer cells and may represent a risk factor for deep vein thrombosis. Enoxaparin has been used to prevent formation of blood clots in patients after abdominal or orthopedic surgery and in patients who suffer from a severe medical illness. Based on these studies, we are investigating to see if it prevents thrombosis in people with certain types of cancer. Recruiting 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer 19 Pancreatic Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/19-pancreatic-cancer 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 3 103 http://clinicaltrials.dfhcc.harvard.edu/trials/103 Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients The purpose of this study is to compare the efficacy of AZD6244 in combination with docetaxel versus docetaxel alone in patients with KRAS mutation positive locally advanced or metastatic non small cell lung cancer. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 2 221 http://clinicaltrials.dfhcc.harvard.edu/trials/221 Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate The purposes of this study are: to determine the feasibility of administering adjuvant cisplatin plus ALIMTA to patients who undergo surgery with heated cisplatin during surgery; to determine the effects (good and bad) of this combined modality approach in patients with mesothelioma; to evaluate cisplatin effects by determining where it goes and how it is excreted in the body from the collection of tissues and cisplatin samples; to collect and analyze discarded samples of mesothelioma tumor during surgery to help determine the genetic make-up of the disease. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 2 314 http://clinicaltrials.dfhcc.harvard.edu/trials/314 Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer The purpose of this research study is to learn more about whether the combination of drugs carboplatin, Abraxane and Avastin helps treat non-small cell lung cancer (NSCLC). One of the standard treatments for advanced NSCLC is the combination of the drugs carboplatin, paclitaxel and Avastin. Paclitaxel can be associated with severe side effects that may make the treatment difficult to tolerate. Some of these side effects are caused by the solution used to dissolve paclitaxel before it can be administered. Abraxane is a different form of paclitaxel that does not need to be dissolved by this solution. Abraxane is approved for the treatment of breast cancer but is not approved to treat NSCLC. We will also be trying to learn more about how the drug Avastin may work to treat cancer. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 2 317 http://clinicaltrials.dfhcc.harvard.edu/trials/317 Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer RATIONALE: Drugs used in chemotherapy, such as pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving pemetrexed together with sunitinib may kill more tumor cells. It is not yet known whether pemetrexed and sunitinib are more effective when given alone or together in treating non-small cell lung cancer. PURPOSE: This randomized phase II trial is studying pemetrexed and sunitinib to compare how well they work when given alone or together as second-line therapy in treating patients with stage IIIB or stage IV non-small cell lung cancer. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 2 335 http://clinicaltrials.dfhcc.harvard.edu/trials/335 Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR In this research study erlotinib will be given to eligible participants whose lung cancer has been removed by surgery. Eligible patients have adenocarcinoma, a type of non-small lung cancer, and must have 1 or more of the following characteristics: be female, be of Asian or Pacific Rim descent and/or be a never smoker. The potential participant's tumor will be examined for Epidermal growth factor (EGFR) mutations. EGFR is a protein that is overexpressed in most non-small cell lung cancers. Some EGFR has been found to have specific mutations and the participant must have one of these mutations in his tumor. Erlotinib blocks this protein and may control tumor growth and increase survival. Previous research has shown that erlotinib is most effective for people who have these specific mutations in the EGFR. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 2 817 http://clinicaltrials.dfhcc.harvard.edu/trials/817 Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Computed tomography (CT)-guided radiofrequency ablation may be an effective treatment for non-small cell lung cancer. PURPOSE: This phase II trial is studying how well radiofrequency ablation works in treating patients with stage I non-small cell lung cancer. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 2 1346 http://clinicaltrials.dfhcc.harvard.edu/trials/1346 Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced Non-small Cell Lung Cancer (NSCLC) and (EGFR) Mutations The purpose of this research study is to learn if adding hydroxychloroquine (HCQ) to erlotinib helps treat non-small cell lung cancer (NSCLC). Another goal of this research study is to learn more about NSCLC and how it may respond to study treatment. Erlotinib (Tarceva) is a type of drug called a tyrosine kinase inhibitor (TKI). TKIs block a protein called the epidermal growth factor receptor (EGFR). EGFR may control tumor growth and tumor cell survival. However, although TKI drugs can work for some lung cancer patients for a period of time, eventually the tumor finds a way to resist or counteract the TKI treatment and it begins to grow again. Hydroxychloroquine (HCQ) is a drug approved by the FDA for treating malaria, rheumatoid arthritis, and several other diseases. Laboratory research suggests that when HCQ is given with a TKI, it may help delay or prevent TKI resistance from developing. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 2 125 http://clinicaltrials.dfhcc.harvard.edu/trials/125 A Study of XL184 With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer In Phase 1 of this study, the purpose is to evaluate the safety, tolerability, and highest safe dose of the multiple receptor tyrosine kinase inhibitor (including VEGFR2, MET, and RET) XL184 in combination with the EGFR inhibitor erlotinib administered to adults with Non-Small-Cell Lung Cancer (NSCLC). In Phase 2 of this study, the purpose is to evaluate the objective response rate of daily oral administration of XL184 with or without erlotinib in subjects with NSCLC who have progressed after responding to treatment with erlotinib. Target enrollment of Phase 1 is approximately 18 subjects, and target enrollment in Phase 2 is up to 68 subjects (34 subjects in each arm). Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 1/Phase 2 140 http://clinicaltrials.dfhcc.harvard.edu/trials/140 Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer The primary purpose of this study is to determine if we can identify the first lymph node that drains from the tumor, and thus would be the most likely site for metastatic disease, and remove it for analysis to improve the ability to detect tumor in this node and to remove this additional site that potentially contains tumor cells. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 1/Phase 2 302 http://clinicaltrials.dfhcc.harvard.edu/trials/302 A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies The Phase 1 portion of the study will evaluate the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose. (This portion of the study is complete). The Phase 2a portion of the study will evaluate ABT-263 at the defined recommended Phase 2 dose to obtain additional safety information and a preliminary assessment of efficacy. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 1/Phase 2 1067 http://clinicaltrials.dfhcc.harvard.edu/trials/1067 Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 1/Phase 2 65 http://clinicaltrials.dfhcc.harvard.edu/trials/65 A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies The purpose of this study is to determine the safety and effectiveness of MDX-1106 in patients with certain types of cancer. Another purpose is to determine how MDX-1106 is absorbed and distributed within the body, and how it's eventually eliminated. Recruiting 24 Prostate Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/24-prostate-cancer 16 Melanoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/16-melanoma 10 Kidney Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/10-kidney-cancer 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 1 207 http://clinicaltrials.dfhcc.harvard.edu/trials/207 Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma RATIONALE: After removal of visible cancer in the chest, chemotherapy drugs are used to kill or stop tumor cells from dividing, so that they stop growing or/and die. Cisplatin is currently used safely as in intra-operative treatment for malignant pleural mesothelioma. This study is aimed to determine if the addition of gemcitabine as a second intracavitary chemotherapy can be accomplished safely. PURPOSE: This is a Phase I trial to study the efficacy of combination chemotherapy consisting of gemcitabine and cisplatin administered in the operating room and put into the chest and abdomen for one hour. We are also looking at the effects of heating the chemotherapy to a temperature of 42 degrees Celsius and the effect of cytoprotection agents: amifostine and sodium thiosulfate to counteract potential side effects of chemotherapy. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer Phase 1 315 http://clinicaltrials.dfhcc.harvard.edu/trials/315 Lung Cancer Symptom Assessment and Management Intervention The purpose of this study is to develop and test the usability of a computerized symptom assessment and management intervention system in a laboratory setting. The investigators will be asking Health Care Providers (HCPs) to participate in this portion of the study. The second purpose of this study is to work on and improve the computer system that will help collect information about some of the symptoms patients with lung cancer are experiencing as well as medications and supportive care services they have used during their cancer treatment. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer N/A 237 http://clinicaltrials.dfhcc.harvard.edu/trials/237 Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease This research study is being done because patients with a history of chest radiation treatment for Hodgkin's disease have been shown to be at increased risk for developing lung cancer a number of years out from treatment. The risk appears to be further increased among patients with a smoking history. Currently, the practice is to recommend annual low-dose chest CT scans in survivors of Hodgkin's disease who have received prior chest radiation treatment and who have at least a moderate smoking history. In this study, the CT scans will be read and interpreted by the study radiologist, and the results recorded in a consistent manner. Recruiting 14 Hodgkin's Lymphoma http://clinicaltrials.dfhcc.harvard.edu/diagnoses/14-hodgkin-s-lymphoma 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer N/A 1340 http://clinicaltrials.dfhcc.harvard.edu/trials/1340 Computer-Based Comprehensive Geriatric Assessment in Oncology for Individuals 70 or Older With Colorectal, Breast or Lung Cancer Older individuals account for one-third of new cancer cases and cancer-related deaths in the United States. Older individuals are more susceptible to having a decrease in physical and mental function following chemotherapy treatment. Geriatric assessment may provide a way to identify those older individuals at greatest risk of functional decline before treatment starts and during the period of treatment. Geriatric assessment includes a set of screening questions and tests designed to determine the physical and mental status of the individual at a point in time. Geriatric assessment also includes review of medications and other medical conditions the individual may have that may affect function. The investigators are conducting this study to determine if older individuals are able to complete the geriatric assessment using a computer format and how that corresponds to their treating physician's assessment of their functional status before and after starting a new chemotherapy treatment for colon, rectal, breast or lung cancer. The investigators will also evaluate the usefulness of a computerized form of geriatric assessment. Recruiting 3 Breast Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/3-breast-cancer 5 Colorectal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/5-colorectal-cancer 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer N/A 1196 http://clinicaltrials.dfhcc.harvard.edu/trials/1196 GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor. A course of 13 injections will be administered over 27 months. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer 1204 http://clinicaltrials.dfhcc.harvard.edu/trials/1204 A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) This is a randomized, placebo-controlled, double blind phase 2 study designed to compare treatment with ARQ 197 plus erlotinib to erlotinib plus placebo in patients with non-small cell lung cancer. The study will enroll patients who have had one prior chemotherapy regimen (other than erlotinib) for NSCLC. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer 1211 http://clinicaltrials.dfhcc.harvard.edu/trials/1211 PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib. To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer 1215 http://clinicaltrials.dfhcc.harvard.edu/trials/1215 Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. PURPOSE: This randomized phase III trial is comparing three different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer 1225 http://clinicaltrials.dfhcc.harvard.edu/trials/1225 Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether sunitinib is more effective than a placebo in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying sunitinib to see how well it works when given as maintenance therapy compared with a placebo in treating patients with stage III or stage IV non-small cell lung cancer previously treated with combination chemotherapy. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer 1244 http://clinicaltrials.dfhcc.harvard.edu/trials/1244 A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy. This single arm study in patients with advanced Stage IIIb/IV NSCLC who have progressive disease after deriving clinical benefit (defined as response or stable disease after 12 weeks) from second or third line Tarceva monotherapy will determine the proportion of patients with progression-free survival at 12 weeks following combination therapy with R1507 and Tarceva. Patients will receive R1507 (9mg/kg iv) weekly in combination with Tarceva (150mg oral daily) for up to a maximum of 24 months. Other disease-related endpoints including overall survival, objective response rate, time to response, time to progressive disease and duration of response will also be evaluated. The anticipated time on study treatment is 1-2 years, and the target sample size is <100 individuals. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer 1256 http://clinicaltrials.dfhcc.harvard.edu/trials/1256 PF-00299804 As a Single Oral Agent In Untreated Adenocarcinoma Of The Lung In Non-Smokers Or Former Light Smokers This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (<100 cigarette, cigar or pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15 years) Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer 1265 http://clinicaltrials.dfhcc.harvard.edu/trials/1265 A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer This study will compare overall survival in patients with Stage IIIB or IV nonsquamous non-small cell lung cancer. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer 1273 http://clinicaltrials.dfhcc.harvard.edu/trials/1273 A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC The purpose of this study is to improve disease control and survival for patients who were treated with chemotherapy using BMS-690514 over erlotinib Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer 1422 http://clinicaltrials.dfhcc.harvard.edu/trials/1422 Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer The study has a safety and a Phase 2 portion. In the safety portion of the study, subjects with metastatic non-small cell lung cancer will be treated with study drug (CS-7017) in combination with carboplatin and paclitaxel to evaluate safety. In the Phase 2 portion of the study, subjects will receive study drug (CS-7017) or placebo in combination with carboplatin and paclitaxel to evaluate effectiveness and safety. The study will find out if adding CS-7017 to carboplatin and paclitaxel will be safe and improve progression free survival in subjects with metastatic non-small cell lung cancer. Recruiting 13 Lung Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/13-lung-cancer